Summary of Study ST002919

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001814. The data can be accessed directly via it's Project DOI: 10.21228/M87D9M This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002919
Study TitleShort-term metabolic insulin response of DINCH- and MINCH-treated cells
Study SummaryIn the second part of the project, we examined the short-term metabolic insulin response of DINAH- and MINCH-treated cells and compared them with rosiglitazone-differentiated cells. For this purpose, the human SGBS preadipocyte cell line was exposed to differentiation media conditioned with DINCH (10 nM or 10 µM), MINCH (10 nM or 10 µM), or rosiglitazone, and the insulin response was measured by analyzing the changes in glycolysis and PPP between insulin-stimulated and non-insulin-stimulated cells. In conclusion, the insulin response of glycolysis and PPP of cells treated with 10 µM MINCH, but not with 10 nM MINCH or DINCH, was similar to cells differentiated with rosiglitazone.
Helmholtz Centre for Environmental Research
Last NameEngelmann
First NameBeatrice
AddressPermoserstr. 15
Submit Date2023-10-08
Raw Data AvailableYes
Raw Data File Type(s)wiff
Analysis Type DetailLC-MS
Release Date2023-11-01
Release Version1
Beatrice Engelmann Beatrice Engelmann application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR001814
Project DOI:doi: 10.21228/M87D9M
Project Title:MINCH causes metabolic rewiring towards lipid accumulation and adipogenesis
Project Summary:Humans are ubiquitously exposed to plastic additives, including plasticizers. There is growing evidence that exposure to certain plasticizers is associated with the development of obesity due to their metabolism-disrupting properties. Following the restriction of the use of the phthalate plasticizer di-(2-ethylhexyl) phthalate (DEHP) due to its adverse health effects, it has been replaced by new substitutes such as the plasticizer diisononylcyclohexane-1,2-dicarboxylate (DINCH). Despite recent studies suggesting that the primary metabolite monoisononylcyclohexane-1,2-dicarboxylic acid ester (MINCH) promotes human adipocyte differentiation, the adipogenic properties of MINCH remain controversial. Because the metabolome largely reflects the molecular phenotype and is sensitive to perturbation by external factors, we used targeted metabolomics to investigate the effects of DINCH and MINCH on key metabolic pathways of adipocytes. Analysis of central carbon metabolism is particularly relevant because it provides cellular energy through the degradation of organic compounds and metabolic precursors for anabolic functions that are critical for adipocyte function, such as de novo lipogenesis. The project consists of three main studies: analysis of the effects of DINCH and MINCH on central carbon metabolism of human SGSB cells, analysis of the insulin response of DINCH- and MINCH-treated SGSB cells, and analysis of the effects of DINCH and MINCH on central carbon metabolism of human SGSB cells in the presence of the PPARG inhibitor GW9662.
Institute:Helmholtz Centre for Environmental Research
Last Name:Engelmann
First Name:Beatrice
Address:Permoserstr. 15


Subject ID:SU003032
Subject Type:Cultured cells
Subject Species:Homo sapiens
Taxonomy ID:9606


Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Replicate
SA316808MINCH_High_-_1DINCH 10µM minus Insulin 1
SA316809DINCH_High_-_1DINCH 10µM minus Insulin 1
SA316810DINCH_High_-_2DINCH 10µM minus Insulin 2
SA316811MINCH_High_-_2DINCH 10µM minus Insulin 2
SA316812MINCH_High_-_3DINCH 10µM minus Insulin 3
SA316813DINCH_High_-_3DINCH 10µM minus Insulin 3
SA316814MINCH_High_-_4DINCH 10µM minus Insulin 4
SA316815DINCH_High_-_4DINCH 10µM minus Insulin 4
SA316816MINCH_High_-_5DINCH 10µM minus Insulin 5
SA316817DINCH_High_-_5DINCH 10µM minus Insulin 5
SA316798MINCH_High_SN_-_1DINCH 10µM minus Insulin supernatant 1
SA316799DINCH_High_SN_-_1DINCH 10µM minus Insulin supernatant 1
SA316800DINCH_High_SN_-_2DINCH 10µM minus Insulin supernatant 2
SA316801MINCH_High_SN_-_2DINCH 10µM minus Insulin supernatant 2
SA316802DINCH_High_SN_-_3DINCH 10µM minus Insulin supernatant 3
SA316803MINCH_High_SN_-_3DINCH 10µM minus Insulin supernatant 3
SA316804DINCH_High_SN_-_4DINCH 10µM minus Insulin supernatant 4
SA316805MINCH_High_SN_-_4DINCH 10µM minus Insulin supernatant 4
SA316806DINCH_High_SN_-_5DINCH 10µM minus Insulin supernatant 5
SA316807MINCH_High_SN_-_5DINCH 10µM minus Insulin supernatant 5
SA316828DINCH_High_+_1DINCH 10µM plus Insulin 1
SA316829MINCH_High_+_1DINCH 10µM plus Insulin 1
SA316830DINCH_High_+_2DINCH 10µM plus Insulin 2
SA316831MINCH_High_+_2DINCH 10µM plus Insulin 2
SA316832MINCH_High_+_3DINCH 10µM plus Insulin 3
SA316833DINCH_High_+_3DINCH 10µM plus Insulin 3
SA316834MINCH_High_+_4DINCH 10µM plus Insulin 4
SA316835DINCH_High_+_4DINCH 10µM plus Insulin 4
SA316836DINCH_High_+_5DINCH 10µM plus Insulin 5
SA316837MINCH_High_+_5DINCH 10µM plus Insulin 5
SA316818MINCH_High_SN_+_1DINCH 10µM plus Insulin supernatant 1
SA316819DINCH_High_SN_+_1DINCH 10µM plus Insulin supernatant 1
SA316820MINCH_High_SN_+_2DINCH 10µM plus Insulin supernatant 2
SA316821DINCH_High_SN_+_2DINCH 10µM plus Insulin supernatant 2
SA316822MINCH_High_SN_+_3DINCH 10µM plus Insulin supernatant 3
SA316823DINCH_High_SN_+_3DINCH 10µM plus Insulin supernatant 3
SA316824MINCH_High_SN_+_4DINCH 10µM plus Insulin supernatant 4
SA316825DINCH_High_SN_+_4DINCH 10µM plus Insulin supernatant 4
SA316826DINCH_High_SN_+_5DINCH 10µM plus Insulin supernatant 5
SA316827MINCH_High_SN_+_5DINCH 10µM plus Insulin supernatant 5
SA316768DINCH_Low_-_1DINCH 10nM minus Insulin 1
SA316769MINCH_Low_-_1DINCH 10nM minus Insulin 1
SA316770MINCH_Low_-_2DINCH 10nM minus Insulin 2
SA316771DINCH_Low_-_2DINCH 10nM minus Insulin 2
SA316772MINCH_Low_-_3DINCH 10nM minus Insulin 3
SA316773DINCH_Low_-_3DINCH 10nM minus Insulin 3
SA316774MINCH_Low_-_4DINCH 10nM minus Insulin 4
SA316775DINCH_Low_-_4DINCH 10nM minus Insulin 4
SA316776MINCH_Low_-_5DINCH 10nM minus Insulin 5
SA316777DINCH_Low_-_5DINCH 10nM minus Insulin 5
SA316758DINCH_Low_SN_-_1DINCH 10nM minus Insulin supernatant 1
SA316759MINCH_Low_SN_-_1DINCH 10nM minus Insulin supernatant 1
SA316760DINCH_Low_SN_-_2DINCH 10nM minus Insulin supernatant 2
SA316761MINCH_Low_SN_-_2DINCH 10nM minus Insulin supernatant 2
SA316762DINCH_Low_SN_-_3DINCH 10nM minus Insulin supernatant 3
SA316763MINCH_Low_SN_-_3DINCH 10nM minus Insulin supernatant 3
SA316764DINCH_Low_SN_-_4DINCH 10nM minus Insulin supernatant 4
SA316765MINCH_Low_SN_-_4DINCH 10nM minus Insulin supernatant 4
SA316766MINCH_Low_SN_-_5DINCH 10nM minus Insulin supernatant 5
SA316767DINCH_Low_SN_-_5DINCH 10nM minus Insulin supernatant 5
SA316788MINCH_Low_+_1DINCH 10nM plus Insulin 1
SA316789DINCH_Low_+_1DINCH 10nM plus Insulin 1
SA316790DINCH_Low_+_2DINCH 10nM plus Insulin 2
SA316791MINCH_Low_+_2DINCH 10nM plus Insulin 2
SA316792DINCH_Low_+_3DINCH 10nM plus Insulin 3
SA316793MINCH_Low_+_3DINCH 10nM plus Insulin 3
SA316794DINCH_Low_+_4DINCH 10nM plus Insulin 4
SA316795MINCH_Low_+_4DINCH 10nM plus Insulin 4
SA316796MINCH_Low_+_5DINCH 10nM plus Insulin 5
SA316797DINCH_Low_+_5DINCH 10nM plus Insulin 5
SA316778DINCH_Low_SN_+_1DINCH 10nM plus Insulin supernatant 1
SA316779MINCH_Low_SN_+_1DINCH 10nM plus Insulin supernatant 1
SA316780DINCH_Low_SN_+_2DINCH 10nM plus Insulin supernatant 2
SA316781MINCH_Low_SN_+_2DINCH 10nM plus Insulin supernatant 2
SA316782MINCH_Low_SN_+_3DINCH 10nM plus Insulin supernatant 3
SA316783DINCH_Low_SN_+_3DINCH 10nM plus Insulin supernatant 3
SA316784DINCH_Low_SN_+_4DINCH 10nM plus Insulin supernatant 4
SA316785MINCH_Low_SN_+_4DINCH 10nM plus Insulin supernatant 4
SA316786MINCH_Low_SN_+_5DINCH 10nM plus Insulin supernatant 5
SA316787DINCH_Low_SN_+_5DINCH 10nM plus Insulin supernatant 5
SA316843Rosi_-_1Rosiglitazone minus insulin 1
SA316844Rosi_-_2Rosiglitazone minus insulin 2
SA316845Rosi_-_3Rosiglitazone minus insulin 3
SA316846Rosi_-_4Rosiglitazone minus insulin 4
SA316847Rosi_-_5Rosiglitazone minus insulin 5
SA316838Rosi_SN_-_1Rosiglitazone minus insulin supernatant 1
SA316839Rosi_SN_-_2Rosiglitazone minus insulin supernatant 2
SA316840Rosi_SN_-_3Rosiglitazone minus insulin supernatant 3
SA316841Rosi_SN_-_4Rosiglitazone minus insulin supernatant 4
SA316842Rosi_SN_-_5Rosiglitazone minus insulin supernatant 5
SA316853Rosi_+_1Rosiglitazone plus insulin 1
SA316854Rosi_+_2Rosiglitazone plus insulin 2
SA316855Rosi_+_3Rosiglitazone plus insulin 3
SA316856Rosi_+_4Rosiglitazone plus insulin 4
SA316857Rosi_+_5Rosiglitazone plus insulin 5
SA316848Rosi_SN_+_1Rosiglitazone plus insulin supernatant 1
SA316849Rosi_SN_+_2Rosiglitazone plus insulin supernatant 2
SA316850Rosi_SN_+_3Rosiglitazone plus insulin supernatant 3
SA316851Rosi_SN_+_4Rosiglitazone plus insulin supernatant 4
SA316852Rosi_SN_+_5Rosiglitazone plus insulin supernatant 5
Showing results 1 to 100 of 100


Collection ID:CO003025
Collection Summary:The SGBS cells were obtained from Prof. Martin Wabitsch laboratory at the University Clinic Ulm. SGBS preadipocytes were differentiated according to the standard protocol described previously (Wabitsch et al., 2001).
Sample Type:Adipose tissue
Storage Conditions:-80℃


Treatment ID:TR003041
Treatment Summary:SGSB preadipocytes were maintained at 37°C and 5% CO2 in 95% humidity. To examine the insulin response of SGBS treated with DINCH and MINCH, SGBS preadipocytes were treated for 18 days with differentiation media without the PPARG agonist rosiglitazone supplemented with DINCH or MINCH (10 nM and 10 µM). To obtain an adipogenesis reference, SGBS cells were differentiated with rosiglitazone for 18 days according to the standard differentiation protocol. After replacing the medium on day 17 with differentiation medium without insulin and overnight incubation (insulin starvation), cells were starved for 1 hour with differentiation medium without glucose and insulin (glucose + insulin starvation). Subsequently, cells were incubated with either differentiation medium with insulin (insulin-stimulated cells correspond to plus-insulin samples) or without insulin (unstimulated cells correspond to minus-insulin samples). During differentiation, a final concentration of 0.01% (v/v) MeOH and 0.02% (v/v) DMSO was added to all differentiation media. Continuous exposure was mimicked by replacing the cell culture medium every other day. Each treatment was performed in five biological replicates (n=5).

Sample Preparation:

Sampleprep ID:SP003038
Sampleprep Summary:Extraction of intracellular and extracellular metabolites was performed by a 1:1:1 methanol:water:chloroform extraction protocol. For the extraction of intracellular metabolites, the culture medium was removed and the cells were rinsed twice with 1 ml of 0.9% ice-cold NaCl. The rinsing solution was removed, and the metabolism of the cells was stopped by adding 400 µL of MeOH (-20 °C) followed by 400 µL of ice-cold H2O containing 10 µM d6-glutarate. Cells were collected using a cell lifter and 400 µL of chloroform was added. After shaking at 1,400 rpm and 4 °C for 20 min, the extraction mixture was centrifuged at 18,000 g and 4 °C for 5 min. Subsequently, 300 µL volume of the polar upper phase was collected and evaporated to complete dryness. For the extraction of extracellular metabolites, 300 µL of the supernatant was extracted by adding 400 µL MeOH (-20 °C) containing 100 nM MEHP, 100 µL ice-cold H2O containing 40 µM d6-glutarate, and 400 µL chloroform (-20 °C). Subsequent sample preparation was identical to the extraction of intracellular metabolites. Note: After measurement of the samples by LC-MS, the raw AUC values uploaded here were normalized to the internal standard (d6-glutarate, if applicable) and DNA content per well (measured by DAPI fluorescence). After normalization, log2 fold changes were calculated by dividing the normalized peak area from each replicate of each treatment by the normalized peak area from each control. Insulin data were not normalized to DAPI because fold changes were calculated by dividing the intensities of the insulin-stimulated cells by the noninsulin-stimulated cells from each treatment.

Combined analysis:

Analysis ID AN004789
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1290 Infinity II
Column Waters Xselect XP HSS T3 (150 x 2.1mm, 2.5µm)
MS instrument type QTRAP
MS instrument name ABI Sciex 6500+
Units Peak AUC


Chromatography ID:CH003620
Instrument Name:Agilent 1290 Infinity II
Column Name:Waters Xselect XP HSS T3 (150 x 2.1mm, 2.5µm)
Column Temperature:40
Flow Gradient:0-5 min 0% B, 5-9 min 0%- 2% B, 9-9.5 min 2-6% B, 9.5-11.5 min 6% B, 11.5-12 min 6-11% B, 12-13.5 min 11% B, 13.5-15.5 min 11-28% B, 15.5-16.5 min 28-53% B, 16.5-22.5 53% B, 22.5-23 min 53-0% B, 23-33 min 0% B
Flow Rate:0-15.5 min 0.4 mL/min, 15.5-16.5 min 0.4-0.15 mL/min, 16.5-23 min 0.15 mL/min, 23-27 min 0.15-0.4 mL/min, 27-33 min 0.4 mL/min
Solvent A:10mM TBA, 10mM acetic acid, 5% MeOH, 2% IPA in water
Solvent B:100% IPA
Chromatography Type:Reversed phase


MS ID:MS004535
Analysis ID:AN004789
Instrument Name:ABI Sciex 6500+
Instrument Type:QTRAP
MS Comments:For identification and quantitation, a scheduled MRM method was used, with specific transitions for every metabolite. Data acquisition and peak integration were performed in Analyst® software (Version 1.7.1).